Nasdaq exas.

Exact Sciences Corporation’s EXAS legacy Screening business is witnessing significant improvement, buoyed by Cologuard volume growth. However, escalating costs and stiff competition are concerning.

Nasdaq exas. Things To Know About Nasdaq exas.

EXACT Sciences Corporation stock price (EXAS) NASDAQ: EXAS. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert EXACT Sciences Corporation stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Exact Sciences Corp. (EXAS) has a Smart Score of 7 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge …WebNov 9, 2022 · EXACT Sciences Corporation (NASDAQ:EXAS) Number of Hedge Fund Holders: 28. Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products ... Exact Sciences' sales will top $2 billion this year as the business continues to achieve impressive growth. ... NASDAQ: EXAS Exact Sciences. Market Cap. $12B. Today's Change (4.73%) $3.03.Feb 27, 2018 · ADVISORY, Feb. 27, 2018 (GLOBE NEWSWIRE) -- What: Exact Sciences Corp. (Nasdaq:EXAS), a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer, will open the Nasdaq Stock Market remotely from the Cologuard Classic, a PGA TOUR Champions event in Tucson, Arizona.

EXAS Stock 12 Months Forecast. $95.46. (50.43% Upside) Based on 14 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is $95.46 with a high forecast of $120.00 and a low forecast of $80.00. The average price target represents a 50.43% change from the last price of $63.46.

Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...

EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission. Find the latest Financials data for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com. Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 14.58 years. total yearly compensation is $14.22M, comprised of 3.6% salary and 96.4% bonuses, including company stock and options. directly owns 0.68% of …Aug 28, 2023 · One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -16.81%, and its shares gained 127.30% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ... Nov 30, 2023 · Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...

Jan 12, 2023 · Exact Sciences' valuation has been plummeting. In 2022, shares of Exact Sciences fell 36%, underperforming the S&P 500, which declined by 19%. Exact Sciences isn't near its 52-week low of $29.27 ...

On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...

Find out the direct holders, institutional holders and mutual fund holders for Exact Sciences Corporation (EXAS).EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.May 11, 2023 · Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ... Oct 9, 2023 · MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ... At Stock Options Channel, our YieldBoost formula has looked up and down the EXAS options chain for the new July 8th contracts and identified one put and one call contract of particular interest ...Find the latest Earnings Report Date for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.For the three-month period ended September 30, 2023, as compared to the same period of 2022, Exact Sciences Corp ( NASDAQ:EXAS) reported a 20% increase in total revenue, reaching $628.3 million ...

Exact Sciences Corp ( NASDAQ:EXAS) is working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients worldwide. The company has reported a net ...Nov 2, 2023 · Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. ... Exact Sciences (EXAS 4.73%) Q3 2023 Earnings Call Nov 01, 2023, 5:00 p.m. ET. Contents: EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ...Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.

Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38.05% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...

Exact Sciences Co. (NASDAQ:EXAS) Insider Sells $864,835.43 in Stock marketbeat.com - October 13 at 8:39 PM: Baillie Gifford & Co. Sells 215,265 Shares of Exact Sciences Co. (NASDAQ:EXAS) marketbeat.com - October 12 at 3:16 PM: Exact Sciences upgraded at Piper Sandler on compelling entry point seekingalpha.com - October 12 at …In trading on Friday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $46.11, changing hands as low as $45.88 per share. EXACT Sciences Corp. shares are ...Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00. Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...After Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...

Discover historical prices for EXAS stock on Yahoo Finance. View daily, weekly or monthly format back to when Exact Sciences Corporation stock was issued. ... Nasdaq 14,158.41-100.08 (-0.70% ...

Dec 4, 2023 · Frontier Capital Management Co. LLC decreased its position in shares of Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 29.1% during the 2nd quarter, according to its most recent disclosure ...

EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on …WebAnalyst's Opinion · Consensus Rating. Exact Sciences has received a consensus rating of Moderate Buy. · Price Target Upside/Downside. According to analysts' ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Exact Sciences Corporation (NASDAQ:EXAS) is a leading global provider of cancer screening and diagnostic test products. On November 3, EXACT Sciences Corporation (NASDAQ:EXAS) announced earnings ...Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st.The medical research company reported ($0.45) EPS for the quarter, beating ...Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...Fintel reports that on May 10, 2023, B of A Securities maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Buy recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...

The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,420 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection. The company offers laboratory testing services from its Cologuard ...Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WebInstagram:https://instagram. stock eatonbest coibroadcom tickerstocks funded account Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin... calavo growerswhat is a mortgage reit Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. cigna dental plus On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...Exact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...